The BioEnterprise Incubator in University Circle provides a resource that is critically needed yet difficult to find for biopharmaceutical and medical device startups: affordable wet and dry lab space.

The BioEnterprise Incubator is the only place in Northeast Ohio outside of a major healthcare or academic institution where startups in these two sectors can conduct the research needed to commercialize their technologies. That environment removes a significant barrier to growth by providing not just lab space but also shared services and infrastructure.

**BIOENTERPRISE INCUBATOR AMENITIES**

- Wet and dry lab space including state-of-the-art fume hoods, freezers, incubators, autoclaves, quantitative tools and other laboratory equipment
- Office space with flexible workstations, private offices, conference rooms and shared office amenities
- Close proximity to Cleveland Clinic, University Hospitals and Case Western Reserve University
- Access to BioEnterprise Executives-in-Residence and analysts to provide assistance in company formation, diligence, go-to-market strategy, potential partnerships and more

**INCUBATOR SUCCESS STORIES**

**BioMotiv:** Drug development acceleration partner to UH Harrington Discovery Institute within Harrington Project for Discovery and Development. Launched at BioEnterprise Incubator, with $145M in growth capital raised to date and a recently announced partnership with pharmaceutical giant Bristol-Myers Squibb.

**Athersys:** First tenant of the BioEnterprise Incubator in 2002, where it developed a pharmaceutical stem cell therapy called MultiStem to treat diseases and conditions in the neurological, inflammatory and immune, and cardiovascular areas. Now a $255M company that went public in 2007.

**Convelo Therapeutics:** Developer of regenerative medicines to treat multiple sclerosis. Raised $13M in growth capital since 2017 with on-loan BioEnterprise employees to fuel growth. In 2019, entered strategic partnership with Genentech with an option to acquire.

**CardioInsight:** Invented a non-invasive mapping technology for electrical disorders of the heart in 2004, commercialized by CWRU researchers. Raised $37M in growth capital before being acquired by Medtronic in 2015.

**Haima Therapeutics:** Launched in 2015 to commercialize a synthetic platelet technology for treatment of traumatic bleeding. Now has 6 employees at the BioEnterprise Incubator and recently received $300K grant from the NIH National Heart, Lung and Blood Institute.